DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Time to Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped up prior to trading on Friday. The stock had previously closed at $84.00, but opened at $88.21. DiaSorin shares last traded at $88.21, with a volume of 2 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have commented on DSRLF shares. BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Zacks Research raised DiaSorin from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. UBS Group cut DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of DiaSorin in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, DiaSorin presently has an average rating of “Strong Sell”.

DiaSorin Price Performance

The stock has a 50-day moving average price of $85.53 and a 200 day moving average price of $78.30.

About DiaSorin

DiaSorin S.p.A. is an Italian healthcare company that develops, manufactures and markets in vitro diagnostic products. Its portfolio is focused on immunodiagnostics and molecular diagnostics used to support the detection and monitoring of diseases and medical conditions.

The company offers diagnostic assays, reagents and analytical systems for areas including infectious diseases, endocrinology, oncology, autoimmune disorders, bone and mineral metabolism, cardiovascular conditions and gastrointestinal diseases.